Psilocybin
Psyched Wellness extract shows positive potential for brain health improvement
The Amanita muscaria extract was the subject of research published last month in Frontiers in Pharmacology
The post Psyched Wellness extract shows positive…
A new study published in the journal Frontiers in Pharmacology has shown that an Amanita muscaria mushroom extract developed by Psyched Wellness (CSE: PSYC) (OTC Pink: DCNPF) could be capable of positively modulating brain health.
The study was published on April 12 and Psyched announced the results on Tuesday. They showed that the company’s extract activates human microglia, the primary immune cells in the central nervous system (CNS).
The research was conducted by the National Research Council of Canada, and for the first time the group has demonstrated that Amanita muscaria can activate human microglia cells grown in lab cultures. This activation triggers the production of immune mediators that could mobilize other immune cells within the brain and induce positive changes in neuronal function.
“The potential priming effect results in a more efficient response of these cells to help maintain brain maintenance and thus sustainment of normal brain functions,” said Brian Tancowny, a Scientific Advisor for Psyched Wellness.
The peer-reviewed study highlights the significant role of Amanita muscaria in modulating the immune response in the brain through the activation of those microglia cells. Microglia cells play a vital role in maintaining brain health by clearing the CNS of infectious agents, plaques, damaged neurons and excess synapses which can disrupt normal brain functioning.
It is particularly relevant because neuroinflammation and immune-induced changes in the brain have been implicated in various conditions, including migraines, depression and altered sleep patterns. Therefore, understanding the mechanisms underlying microglia activation can provide valuable insights into the development of these conditions and potential therapeutic interventions.
“This data suggests that the AME-1 extract may prime microglial cells toward a protective innate immune response facilitated by TLR3,” reads the study. TLR3 is a type of protein that plays a crucial role in the immune system.
@PsychedWellness is doing some of the most interesting research into a powerful mushroom that has largely been ignored by #psychedelic researchers.
New study shows neuron changes that could lead to improved sleep and depression symptoms https://t.co/O4T6Eg6Zf0
— Nik Vassev (@nikvassev) May 2, 2023
Read more: MAPS launches online education program on psychedelics
Read more: Psyched Wellness formulates first commercial Amanita muscaria extract
The group also demonstrated that Amanita muscaria extracts contain crucial metabolites like trehalose, a sugar found in some fungi and yeasts.
This discovery was made possible through the use of metabolite screening technology. Trehalose, which is used in the production of food, beauty products and some pharmaceuticals, could play a vital role in modulating microglial inflammatory responses.
“The National Research Council of Canada based its research on our company’s proprietary Amanita muscaria extract, AME-1, and proved additional benefits of our effective supplement. This is another key finding of function and furthers our understanding of the effects of AME-1” said David Shisel, Chief Operations Officer of Psyched Wellness.
Psyched also announced on Wednesday that the mushroom extract was now available on the website of the American department store Sears. The extract is also currently available on Amazon and at Good Earth Markets locations.
The company’s shares dropped by 14.29 per cent on Wednesday to $0.06 on the Canadian Securities Exchange.
rowan@mugglehead.com
The post Psyched Wellness extract shows positive potential for brain health improvement appeared first on Mugglehead Magazine.
amanita muscaria psychedelic depression amanita psychedelics mushroom shares cse otc psyched wellness psyched psyc research
GH Research advances depression therapies, burns cash
PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
MindBio Therapeutics Scientists Present Landmark Women’s Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month
-
LSD1 week agoThe First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Psilocybin1 week agoPsychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics6 days agoCompass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics6 days agoCybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics5 days agoFreedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics5 days agoBehold! A New Mushroom Emoji Has Arrived!
-
Law & Regulation4 days agoCompass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics5 days ago
Behold! A New Mushroom Emoji Has Arrived!